ELTX Elicio Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why ELTX matters now
Elicio Therapeutics, Inc. (ELTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.98 with -1.97% on the session and $56.8M in market capitalization; recent performance reads 1-month -58.02% and YTD -51.63%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-11.8M, and EPS of $-0.65. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.4%.
The latest indexable market news headline is "Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Haqq Christopher filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-48.79
P/S
0.00
EV/EBITDA
-1.93
DCF Value
$0.22
FCF Yield
-52.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-2748.2%
ROA
-177.1%
ROIC
-227.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-11.8M | $-0.65 |
| Q4 2025 | $0.00 | $-7.7M | $-0.45 |
| FY 2025 | $0.00 | $-39.6M | $-2.58 |
| Q3 2025 | $0.00 | $-10.1M | $-0.60 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$17.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.14
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.